ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Initially, GZD824 was identified as an inhibitor of BCR-ABL, the fusion protein with constitutively active tyrosine kinase activity, commonly associated with chronic myeloid leukemia (176).